Cite
HARVARD Citation
Gross, A. et al. (2022). Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-oncology. 24 (11), pp. 1978-1988. [Online].